unknown
Stage
1
Investors
About
FinalDose is developing a programmable therapeutic molecule that recognizes disease-associated DNA sequences and selectively kills the matching cells. The company is initially focused on applying this DNA-recognition approach to oncology.
Explore FinalDose's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.